Ridgetech reported results for the six months (H1) ended Sept. 30, 2025, with net revenues of USD 62.8 million and gross profit of USD 2.5 million (gross margin 3.9%). The company posted an operating loss of USD 0.1 million and a net loss from continuing operations of USD 0.1 million, while net cash provided by operating activities was USD 5.3 million. Cash and cash equivalents were USD 13.9 million at Sept. 30, 2025, with restricted cash of USD 4.1 million. In business updates, Ridgetech said it operates primarily as a wholesale distributor of pharmaceutical and other healthcare products in China, including offline wholesale and online sales via self-operated and third-party platforms. The company highlighted online platform revenue of USD 11.1 million in H1 2025, reflecting Allright’s contribution following the Feb. 28, 2025 acquisition, and said offline wholesale revenue declined 21.6% to USD 51.7 million after it discontinued some credit sales effective March 2025 due to delayed customer repayments. Subsequent to the period, Ridgetech entered a private placement on Oct. 30, 2025 to sell 4.7 million ordinary shares for gross proceeds of USD 2.8 million and issue warrants for up to 11.7 million ordinary shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ridgetech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-024126), on March 05, 2026, and is solely responsible for the information contained therein.